UNSPSC 51111910: Paclitaxel poliglumex

This classification denotes a taxane compound and paclitaxel preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQ64FZ98ZN. European Medicines Agency schedules Paclitaxel poliglumex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27755.

Paclitaxel poliglumex generally arises in the molecular formula C10H16N2O7(C52H56N2O16)N(C5H7NO3)N. The term PACLITAXEL POLIGLUMEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations schedule paclitaxel poliglumex under HS 39089000 and SITC 57539. As of Q4 2014, PACLITAXEL POLIGLUMEX remains the US FDA Preferred Term for this commodity. Paclitaxel poliglumex bears US NLM identifiers UMLS ID C1702776 and NCI Concept Code C1795.

UNSPSC 51111910 Paclitaxel poliglumex is a Commodity code representing a chemotherapy drug formulation state and local health systems procure for cancer treatment. The code covers paclitaxel poliglumex (brand name Xyotax), a taxane-class chemotherapeutic agent used in oncology protocols, typically purchased by state health departments, county hospital systems, municipal medical centers, and integrated health networks as part of their pharmaceutical inventory. Procurement under this code is driven by clinical formulary requirements and patient treatment protocols rather than routine commodity acquisition — quantities and timing reflect cancer patient census, treatment protocols, and inventory management practices within health systems.

The source provides no recent state and local contract opportunities tagged to this Commodity code. Without posted solicitations, RFPs, RFQs, or ITBs naming paclitaxel poliglumex, geographic concentration and issuing-body patterns cannot be characterized from current market activity.